Anthony Hagen
Advertisement
Articles by Anthony Hagen
The FDA will reassess 6 indications for immune checkpoint inhibitors that were granted accelerated approval but failed to prove clinical benefit in confirmatory trials.
Advertisement
Latest Updated Articles
Conference Coverage: European Hematology Association 2021 Virtual CongressPublished: August 17th 2021 | Updated:
- For Staying Power, Diabetes Interventions May Need a Hands-on Element
Published: January 21st 2015 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Blinatumomab Boosts Survival in Pediatric ALL, but Faces Delivery Hurdles
2
Real-World Safety Signals of Bimekizumab Emerge in New FAERS Analysis
3
ICYMI: Highlights From AACR 2025
4
Legal Issues in Value-Based Care Contracts for Self-Insured Employers
5
